36 research outputs found
Marine harmful algal blooms, human health and wellbeing : challenges and opportunities in the 21st century
Author Posting. © Marine Biological Association of the United Kingdom, 2015. This is the author's version of the work. It is posted here by permission of Marine Biological Association of the United Kingdom for personal use, not for redistribution. The definitive version was published in Journal of the Marine Biological Association of the United Kingdom 96 (2016): 61-91, doi:10.1017/S0025315415001733.Microalgal blooms are a natural part of the seasonal cycle of photosynthetic organisms in marine ecosystems. They are key
components of the structure and dynamics of the oceans and thus sustain the benefits that humans obtain from these aquatic
environments. However, some microalgal blooms can cause harm to humans and other organisms. These harmful algal
blooms (HABs) have direct impacts on human health and negative influences on human wellbeing, mainly through their consequences
to coastal ecosystem services (valued fisheries, tourism and recreation) and other marine organisms and environments.
HABs are natural phenomena, but these events can be favoured by anthropogenic pressures in coastal areas. Global
warming and associated changes in the oceans could affect HAB occurrences and toxicity as well, although forecasting the
possible trends is still speculative and requires intensive multidisciplinary research. At the beginning of the 21st century,
with expanding human populations, particularly in coastal and developing countries, there is an urgent need to prevent
and mitigate HABsâ impacts on human health and wellbeing. The available tools to address this global challenge include
maintaining intensive, multidisciplinary and collaborative scientific research, and strengthening the coordination with stakeholders,
policymakers and the general public. Here we provide an overview of different aspects to understand the relevance
of the HABs phenomena, an important element of the intrinsic links between oceans and human health and wellbeing.The research was funded in part by the UK Medical Research
Council (MRC) and UK Natural Environment Research
Council (NERC) for the MEDMI Project; the National
Institute for Health Research Health Protection Research
Unit (NIHR HPRU) in Environmental Change and Health
at the London School of Hygiene and Tropical Medicine in
partnership with Public Health England (PHE), and in collaboration
with the University of Exeter, University College
London and the Met Office; and the European Regional
Development Fund Programme and European Social Fund
Convergence Programme for Cornwall and the Isles of Scilly
(University of Exeter Medical School).
EB was supported by the CTM2014-53818-R project, from
the Spanish Government (MINECO). KDA was in receipt of
funding from the BBSRC-NERC research programme for
multidisciplinary studies in sustainable aquaculture: health,
disease and the environment. P. Hess was supported by
Ifremer (RISALTOX) and the Regional Council of the Pays
de la Loire (COSELMAR). Porter Hoagland was supported
by the US National Science Foundation under NSF/CNH
grant no. 1009106.2016-05-2
Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.
We assessed the effect of mass azithromycin treatment on malaria parasitemia in a trachoma trial in Niger. Twenty-four study communities received treatment during the wet, high-transmission season. Twelve of the 24 communities were randomized to receive an additional treatment during the dry, low-transmission season. Outcome measurements were conducted at the community-level in children < 1-72 months of age in May-June 2011. Parasitemia was higher in the 12 once-treated communities (29.8%, 95% confidence interval [CI] = 21.5-40.0%) than in the 12 twice-treated communities (19.5%, 95% CI = 13.0-26.5%, P = 0.03). Parasite density was higher in once-treated communities (354 parasites/ÎŒL, 95% CI = 117-528 parasites/ÎŒL) than in twice-treated communities (74 parasites/ÎŒL, 95% CI = 41-202 parasites/ÎŒL, P = 0.03). Mass distribution of azithromycin reduced malaria parasitemia 4-5 months after the intervention. The results suggest that drugs with antimalaria activity can have long-lasting impacts on malaria during periods of low transmission
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD. METHODS: We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56. RESULTS: A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy
Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium
Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, using MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets in the ENIGMA consortium, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macro-structural asymmetry may reflect differences at the molecular, cytoarchitectonic or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia
Blue Carbon Storage Capacity of Temperate Eelgrass (Zostera marina) Meadows
Despite the importance of coastal ecosystems for the global carbon budgets, knowledge of their carbon storage capacity and the factors driving variability in storage capacity is still limited. Here we provide an estimate on the magnitude and variability of carbon stocks within a widely distributed marine foundation species throughout its distribution area in temperate Northern Hemisphere. We sampled 54 eelgrass (Zostera marina) meadows, spread across eight ocean margins and 36° of latitude, to determine abiotic and biotic factors influencing organic carbon (Corg) stocks in Zostera marina sediments. The Corg stocks (integrated over 25âcm depth) showed a large variability and ranged from 318 to 26,523 g C/m2 with an average of 2,721 g C/m2. The projected Corg stocks obtained by extrapolating over the top 1 m of sediment ranged between 23.1 and 351.7 Mg C/ha, which is in line with estimates for other seagrasses and other blue carbon ecosystems. Most of the variation in Corg stocks was explained by five environmental variables (sediment mud content, dry density and degree of sorting, and salinity and water depth), while plant attributes such as biomass and shoot density were less important to Corg stocks. Carbon isotopic signatures indicated that at most sites <50% of the sediment carbon is derived from seagrass, which is lower than reported previously for seagrass meadows. The high spatial carbon storage variability urges caution in extrapolating carbon storage capacity between geographical areas as well as within and between seagrass species
Incorporating epilepsy genetics into clinical practice:A 360° evaluation
AbstractWe evaluated a new epilepsy genetic diagnostic and counseling service covering a UK population of 3.5 million. We calculated diagnostic yield, estimated clinical impact, and surveyed referring clinicians and families. We costed alternative investigational pathways for neonatal onset epilepsy. Patients with epilepsy of unknown aetiology onsetâ<â2 years; treatment resistant epilepsy; or familial epilepsy were referred for counseling and testing. We developed NGS panels, performing clinical interpretation with a multidisciplinary team. We held an educational workshop for paediatricians and nurses. We sent questionnaires to referring paediatricians and families. We analysed investigation costs for 16 neonatal epilepsy patients. Of 96 patients, a genetic diagnosis was made in 34% of patients with seizure onsetâ<â2 years, and 4%â>â2 years, with turnaround time of 21 days. Pathogenic variants were seen in SCN8A, SCN2A, SCN1A, KCNQ2, HNRNPU, GRIN2A, SYNGAP1, STXBP1, STX1B, CDKL5, CHRNA4, PCDH19 and PIGT. Clinician prediction was poor. Clinicians and families rated the service highly. In neonates, the cost of investigations could be reduced from ÂŁ9362 to ÂŁ2838 by performing gene panel earlier and the median diagnostic delay of 3.43 years reduced to 21 days. Panel testing for epilepsy has a high yield among children with onsetâ<â2 years, and an appreciable clinical and financial impact. Parallel gene testing supersedes single gene testing in most early onset cases that do not show a clear genotype-phenotype correlation. Clinical interpretation of laboratory results, and in-depth discussion of implications for patients and their families, necessitate multidisciplinary input and skilled genetic counseling.</jats:p
Recommended from our members
Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.
Therapy-related myeloid neoplasms (t-MN) are a distinct subgroup of myeloid malignancies with a poor prognosis that include cases of therapy-related myelodysplastic syndrome (t-MDS), therapy-related myeloproliferative neoplasms (t-MPN) and therapy-related acute myeloid leukemia (t-AML). Here, we report a series of patients with clinical features consistent with juvenile myelomonocytic leukemia (JMML), an overlap syndrome of MDS and myeloproliferative neoplasms that developed after treatment for another malignancy